Phase 2 Data Shows Maribavir Markedly Reduced Rate Of Cytomegalovirus Infection And Disease In Bone Marrow Transplant Patients
Jun 10th 2008Drug InformationStem Cell Research
ViroPharma Incorporated (Nasdaq: VPHM) announced the publication of results of its previously described Phase 2 study showing that maribavir, when used as prophylaxis, reduced the rate of cytomegalovirus (CMV) reactivation and was well tolerated when compared to placebo in allogeneic stem cell, or bone marrow, transplant patients.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
